In one of the video interviews, Dr. Damaj also addresses the differences in the efficacy of topically applied Vitaros versus oral erectile dysfunction drugs and the reduced level of side effects from topically applied medication versus oral drugs.
About Apricus Biosciences
Backed by NexMed, USA and Bio-Quant, Inc., its revenue generating CRO business, Apricus Bio has leveraged the flexibility of its proven NexACT drug delivery technology to enable multi-route administration of new and improved compounds across numerous therapeutic classes. Future growth is expected to be driven primarily through out-licensing of this technology for the development and commercialization of such compounds to pharmaceutical and biotechnology companies, worldwide. Concurrently, the Company is seeking to monetize its existing product pipeline, including its approved drug erectile dysfunction treatment, Vitaros, as well as compounds in development from pre-clinical through Phase 3, currently focused on dermatology, sexual dysfunction and cancer. For further information on Apricus Bio and its subsidiaries, visit
Apricus Bio’s Forward-Looking Statement Safe Harbor
Statements under the Private Securities Litigation Reform Act: with the exception of the historical information contained in this release, the matters described herein contain forward-looking statements that involve risks and uncertainties that may individually or mutually impact the matters herein described for a variety of reasons that are outside the control of the Company, including, but not limited to, the ability of the Company to consummate licensing and partnership transactions and the timing for these transactions; timing and success for seeking foreign approvals for Vitaros and the timing and success of the commercial launch of Vitaros in Canada. The Company may not achieve the results anticipated by these forward-looking statements and readers are cautioned not to place undue reliance on these forward-looking statements. Readers are urged to read the risk factors set forth in the Company's most recent annual report on Form 10-K and subsequent quarterly reports filed on Form 10-Q for information about these and other factors that could cause actual results to differ from anticipated results. Copies of these reports are available from the SEC's website or without charge from the Company.